CONCLUSION
Several clinical trials have been conducted and completed to assess the
safety and efficacy of GHS for the diagnosis and/or treatment of GH
deficiency. Over the past two decades, scientists’ efforts have focused
on the discovery and biological characterization of new tissue-specific
SARM to promote the beneficial effects of androgens with greatly reduced
undesirable side effects. In this regard, numerous studies with SARM of
different structures have been reported. Despite evidenced clinical and
preclinical studies, no SARM has yet received full clinical approval.